Major League Baseball and the Prostate Cancer Foundation teamed up this year to form the Home Run Challenge in honor of Father's Day. Their gift to father's across the country: for each home run hit in 60 selected games between June 6 and today, June 17, raised money for prostate cancer, the second most common cancer for men in the United States.

Some fans of this cause made pledges; some posted online tributes to their dads at Dockers San Francisco. For every message submitted, the company donated one dollar. Some messages were even shown in Times Square for all to see.

I just checked the status of the Home Run Challenge on this Father's Day morning and found the most updated total of home runs to be 91. Leading the accomplishment are Ken Griffey, Jr., Alex Rodriguez, and Alfonso Soriano. The current Team Home Run leader: the Cincinnati Reds.

Theranostics Health LLC is a company that was formed by George Mason University cancer researchers Dr. Lance Liotta and Emanuel Petricoin.

The company plans to tailor cancer treatments to individual patients based on proteomics, the study of proteins. Proteins play a central role in our bodies. Understanding the structure and function of each protein and its complexities of protein interactions can be critical for developing the most effective diagnostic techniques and disease treatments in the future.

Information about protein activity in tumors can allow doctors to choose the best drugs to kill the cancer cells. President and CEO of the company Joseph Reilly said "The physicians will then be provided a new class of information about that patients' individual cancer. This will enable the physician to tailor the therapy based on the individual patients' tumor."

One size fits all for cancer treatment is hopefully on its way out. We need to prescribe the right therapy to the right patient. This will increase treatment success rates and also spare patients unnecessary toxicity from chemotherapy drugs that would be unsuitable for their tumor.

A new PSA density test may help identify men at high risk of developing prostate cancer.

The test, used after a biopsy finds no signs of life-threatening prostate cancer, can compare the size of a man's prostate to his levels of a cancer-related protein called prostate-specific antigen (PSA).

Even though both men with high and low PSA densities can have clean biopsies, studies show it's men with very high PSA densities who are at greatest risk of developing prostate cancer. This and the fact that biopsies can miss between 20 and 33 percent of tumors makes this new test a potential breakthrough for the prevention and detection of prostate cancer.

A popular baldness drug manufactured by Merck & Co Inc called Finasteride, better know as Propecia, can mask an important marker used to detect prostate cancer. High levels of the PSA in the blood can signal prostate cancer or other problems such as an enlarged prostate.

Propecia has been shown in a study to artificially lower the prostate specific antigen (PSA). Dr. Anthony D'Amico, the lead author of the study from Brigham and Women's Hospital in Boston, recommends middle-aged men taking Propecia to have their PSA levels multiplied by two to account for the difference. He says, "The main finding is that this drug called Propecia, which men use for hair loss typically between the ages of 30-60, affects the PSA levels".

Merck said in a statement that information has been included for customers on the label since the product was first introduced in 1997. It advises patients who undergo serum PSA tests to tell their doctor if they are taking Propecia.

It may be on the label but I hope our doctors are aware of this. Are they asking the patients if they are using Propecia? I'm sure there are plenty of men who have not read the fine print and don't mention this information to their physicians.

Cancer cells sometimes secrete specialized proteins into the bloodstream that serve as indicators of tumor growth. These tumor markers are often distinctly associated with a particular type of cancer. Like prostate cancer.

The most well-known tumor marker today is the PSA -- the prostate-specific antigen. PSA is a highly specific protein that is secreted only by cells of the prostate gland. It is one of the most widely used -- and the only widely accepted -- screening test for cancer.

There's also the tumor marker CA-125, used in the diagnosis of ovarian cancer and in the monitoring of response to treatment for the same disease. There's CEA for colon cancer, CA-19-9 for pancreatic cancer, AFP for liver and testicular cancer, beta-HCG for testicular cancer, and CA 15-3 for breast cancer. And research is under way on newer, more useful tumor markers. This is a good thing -- because some tumor markers are not specific enough or sensitive enough to accurately predict tumor growth.

This is why my oncologist does not recommend I enter the world of tumor markers, despite my status as a breast cancer survivor. He suggests I rely simply on how I feel for monitoring my chances for cancer recurrence. If I experience any worrisome symptoms, he will be the first to wage an all-out assessment of my health. But without symptoms, tumor markers are not likely to help me at all.

A peek at my breast cancer tumor markers would likely be hazy, inconclusive, and not all that helpful. Examination of tumor markers can lead to false positives. It can lead to expensive and often unnecessary follow-up testing. It can lead to worry and panic and even alarm if the numbers are not in the hoped-for range.

Although an abnormal tumor marker level may suggest cancer, this alone is typically not enough to diagnose the disease. Measurements of tumor markers are usually combined with other tests, such as a biopsy, to confirm cancer. So what would I do with an abnormal number and nothing suspicious to biopsy? I would worry. I would panic. Perhaps unnecessarily.

My doctor suggests I refrain from a wild cancer chase. And I am happy with his suggestion. Between my own awareness, follow-up oncology appointments, mammograms, annual OB/GYN check-ups, and more, I am confident any health issues that come my way will be detected early -- and can be resolved in good time. I have no need for confusing tumor marker details. Unless they are conclusively recommended, I will survive without them. More important, I will survive without worry.

PSA tests are a recommended way to screen for prostate cancer, however the test is not very precise. Too much PSA, prostate-specific antigen, in a man's blood can indicate that he has either a benign enlarged prostate or cancer. Only a biopsy can tell the difference.

A new study suggests that physicians should monitor not only the number of the PSA test but also the trend of the results. In other words, if the blood test shows a jump by a few points, even though the number is still in normal range, it could be a sign that the patient has prostate cancer.

The study, published in the Journal of the National Cancer Institute, suggests evaluating how fast a man's PSA level rises may help that tricky balancing act of when to biopsy and how aggressive to treat.

What does that mean for men today? That its a good idea to order a biopsy for a man with a low but fast-rising PSA.

Charlie Emrich, in Glowing chickens bring hope in fight against cancer, calls fluorescent chickens, "cool in a creepy, mad-scientist sort of way." When you consider that scientists have combined jellyfish DNA with chickens to create illuminated birds, you can kind of see it from Emrich's descriptive perspective.

The purpose of chickens that glow, is that scientists can track antibody-based therapies that might prove valuable in treating human cancers.

UC Davis Cancer Center Dr. Joseph Tuscano explains that, "One of the problems with modern drugs is that they're not very specific. Even aspirin is not very specific. Antibodies, on the other hand are highly, highly specific meaning that, like an archer's arrow, they can effectively target a disease. Antibody-based therapies are one of the biggest advances in cancer treatment in the last 40 years."

Emrich quotes researchers of the project and takes you through the purpose and process of genetically-modified glow-in-the-dark chickens in the potential development of antibody-based therapies to one day treat cancer here.

I've been keeping a journal ever since I was first diagnosed with breast cancer. I first wrote by hand in a pink fabric-covered book, sprinkled with multi-colored polka dots. It looked feminine -- which is why I bought it -- and it's vibrance made me feel inspired, motivated, eager to write down the dreaded details of the beginning of my journey. Then I stopped writing in this book and began typing my words in an on-line journal -- a blog. My husband designed the presentation of it, with a pink banner that serves as the backdrop for the title -- my Breast Cancer blog. My first entry was completed on December 21, 2004 and I am still chronicling my journey here. I am also writing for this site -- the Cancer Blog -- and I write whenever and wherever else I can record my words. I do it because it helps me process information in a quiet, calming, introspective way. It soothes me, helps me work through panic and anxiety, helps me heal, and helps me chart my progress. When I look back at what I've written, I realize how far I've come -- or haven't come -- and it helps me move forward. I recommend journaling for everyone, and I recommend these seven simple suggestions for getting started.

When Lindy Snider discovered there were no cosmetics specifically developed to meet the special skin care needs of cancer patients undergoing cancer treatment, she decided to start a cosmetic and skin care product line to meet those needs.

Snider brought together scientists, cancer patients, cancer survivors, oncologists and dermatologists to create cosmetics and skin care products formulated for patients undergoing chemotherapy or radiation.

The base of LindiSkin products is a mixture of plant oils and botanicals. None of the products contain mineral oil. The ingredients are designed to be anti-inflammatory, anti-irritant and anti-itch, but contain no cortisone or steroids.

"Feeling good about yourself is important anytime, but especially when you're experiencing side effects from cancer treatments," states Snider on the homepage of the Lindi Skin website, where you can purchase her products.